All hopes seem to be lost for Lundbeck with Alzheimer’s candidate idalopirdine, as the last two phase III studies have been as disappointing as the first and the group has decided not to pursue a regulatory path for the drug.
BY ELIZABETH MØNSTED JOHANSEN Offentliggjort 08.02.17 kl. 10:52
Log ind for at læse artikler
Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.
The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.
Thanks to a successful gamble on one particular niche, Denmark’s Gubra has managed to quadruple its employee base in just a few years. The two-pronged business is set to expand significantly in the future.
The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.
The sale of Veloxis’ lead product Envarsus XR is still relatively modest, but plans to enter into a slew of distribution deals should give a much needed growth boost in 2017, while new appointments should also push growth and aid the Danish company’s contact with the US FDA.
Novo Nordisk’s US unit has struck a deal with CVS Health for a new savings program that will give some patients up to 80 percent reduction on some of the group’s insulin products. It thus looks like times are changing in the Denmark-based insulin giant.
København har fået endnu en konkurrent om at overtage det Europæiske Lægemiddelagentur, når Storbritannien melder sig ud af EU. Denne gang er det et land, som argumenterer for, at det ikke har et agentur i forvejen.